1. Home
  2. USAS vs LBRX Comparison

USAS vs LBRX Comparison

Compare USAS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Americas Gold and Silver Corporation no par value

USAS

Americas Gold and Silver Corporation no par value

HOLD

Current Price

$4.66

Market Cap

1.7B

ML Signal

HOLD

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$42.89

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USAS
LBRX
Founded
1998
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2004
2025

Fundamental Metrics

Financial Performance
Metric
USAS
LBRX
Price
$4.66
$42.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.50
$46.60
AVG Volume (30 Days)
4.4M
241.5K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$174.68
N/A
Revenue Next Year
$53.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$13.40
52 Week High
$10.50
$50.16

Technical Indicators

Market Signals
Indicator
USAS
LBRX
Relative Strength Index (RSI) 43.19 46.94
Support Level $4.51 $22.85
Resistance Level $5.19 $49.74
Average True Range (ATR) 0.28 2.05
MACD -0.09 -0.83
Stochastic Oscillator 11.58 7.64

Price Performance

Historical Comparison
USAS
LBRX

About USAS Americas Gold and Silver Corporation no par value

Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: